Tags

Type your tag names separated by a space and hit enter

Comparison of azithromycin vs doxycycline prophylaxis in leptospirosis, A randomized double blind placebo-controlled trial.
J Infect Dev Ctries. 2018 11 30; 12(11):991-995.JI

Abstract

INTRODUCTION

Leptospirosis is an important zoonotic disease in paddy field with 29.5% prevalence rate in Mazandaran province and 4% to 52% mortality rate among hospitalized patients. Prevention is an important strategy for the control of this disease. This study aimed to compare the prophylactic effect of azithromycin versus doxycycline against leptospirosis in an endemic area in north of Iran.

METHODOLOGY

In this randomized double-blind placebo-controlled trial, paddy field workers (n = 187) were randomized to receive azithromycin (500mg weekly), doxycycline (200 mg weekly) or placebo starting one week before exposure to paddy field, during and to four weeks after. Paddy field workers aged 18- 65 years who signed the informed consent form were assessed for signs and symptoms of leptospirosis in addition to serologic evidence of the disease 6th and 12th week. Data were analyzed with SPSS version 13 using Chi-square and Fisher exact test and ANOVA.

RESULTS

From June to September 2016, 187 participants were entered the study to receive azithromycin (n = 66), doxycycline (n = 71) or placebo (n = 50). In terms of preventing against clinical leptospirosis, there was not any significant difference between three arms, though there was statistically significant difference of seropositivity after 6 and 12 weeks in comparison to baseline among all three groups (P = 0.029) and between active treatment (eg. azithromycin and doxycycline) groups and placebo group (P = 0.01).

CONCLUSION

Azithromycin like doxycycline decreased seropositivity without significant effect on clinical leptospirosis.

Authors+Show Affiliations

Mazandaran University of Medical Sciences, Sari, Iran. ahalikhani@yahoo.com.Mazandaran University of Medical Sciences, Sari, Iran. esalehifar52@gmail.com.Mazandaran University of Medical Sciences, Sari, Iran. pzameni3@yahoo.com.Mazandaran University of Medical Sciences, Sari, Iran. rafiei1710@gmail.com.Mazandaran University of Medical Sciences, Sari, Iran. jamshid_1380@yahoo.com.Mazandaran University of Medical Sciences, Sari, Iran. leila.delavarian@yahoo.com.Mazandaran University of Medical Sciences, Sari, Iran. azi-akbari61@gmail.com.Mazandaran University of Medical Sciences, Sari, Iran. farhang.baba@yahoo.com.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32012129

Citation

Alikhani, Ahmad, et al. "Comparison of Azithromycin Vs Doxycycline Prophylaxis in Leptospirosis, a Randomized Double Blind Placebo-controlled Trial." Journal of Infection in Developing Countries, vol. 12, no. 11, 2018, pp. 991-995.
Alikhani A, Salehifar E, Zameni F, et al. Comparison of azithromycin vs doxycycline prophylaxis in leptospirosis, A randomized double blind placebo-controlled trial. J Infect Dev Ctries. 2018;12(11):991-995.
Alikhani, A., Salehifar, E., Zameni, F., Rafiei, A., Yazdani-Charati, J., Delavaryan, L., Akbari, A., & Babamahmoudi, F. (2018). Comparison of azithromycin vs doxycycline prophylaxis in leptospirosis, A randomized double blind placebo-controlled trial. Journal of Infection in Developing Countries, 12(11), 991-995. https://doi.org/10.3855/jidc.10126
Alikhani A, et al. Comparison of Azithromycin Vs Doxycycline Prophylaxis in Leptospirosis, a Randomized Double Blind Placebo-controlled Trial. J Infect Dev Ctries. 2018 11 30;12(11):991-995. PubMed PMID: 32012129.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of azithromycin vs doxycycline prophylaxis in leptospirosis, A randomized double blind placebo-controlled trial. AU - Alikhani,Ahmad, AU - Salehifar,Ebrahim, AU - Zameni,Fatemeh, AU - Rafiei,Alireza, AU - Yazdani-Charati,Jamshid, AU - Delavaryan,Leila, AU - Akbari,Azita, AU - Babamahmoudi,Farhang, Y1 - 2018/11/30/ PY - 2017/12/31/received PY - 2018/09/14/accepted PY - 2020/2/4/entrez PY - 2018/11/30/pubmed PY - 2020/3/31/medline KW - azithromycin KW - chemoprophylaxis KW - clinical trial KW - doxycycline KW - leptospirosis SP - 991 EP - 995 JF - Journal of infection in developing countries JO - J Infect Dev Ctries VL - 12 IS - 11 N2 - INTRODUCTION: Leptospirosis is an important zoonotic disease in paddy field with 29.5% prevalence rate in Mazandaran province and 4% to 52% mortality rate among hospitalized patients. Prevention is an important strategy for the control of this disease. This study aimed to compare the prophylactic effect of azithromycin versus doxycycline against leptospirosis in an endemic area in north of Iran. METHODOLOGY: In this randomized double-blind placebo-controlled trial, paddy field workers (n = 187) were randomized to receive azithromycin (500mg weekly), doxycycline (200 mg weekly) or placebo starting one week before exposure to paddy field, during and to four weeks after. Paddy field workers aged 18- 65 years who signed the informed consent form were assessed for signs and symptoms of leptospirosis in addition to serologic evidence of the disease 6th and 12th week. Data were analyzed with SPSS version 13 using Chi-square and Fisher exact test and ANOVA. RESULTS: From June to September 2016, 187 participants were entered the study to receive azithromycin (n = 66), doxycycline (n = 71) or placebo (n = 50). In terms of preventing against clinical leptospirosis, there was not any significant difference between three arms, though there was statistically significant difference of seropositivity after 6 and 12 weeks in comparison to baseline among all three groups (P = 0.029) and between active treatment (eg. azithromycin and doxycycline) groups and placebo group (P = 0.01). CONCLUSION: Azithromycin like doxycycline decreased seropositivity without significant effect on clinical leptospirosis. SN - 1972-2680 UR - https://www.unboundmedicine.com/medline/citation/32012129/Comparison_of_azithromycin_vs_doxycycline_prophylaxis_in_leptospirosis_A_randomized_double_blind_placebo_controlled_trial_ L2 - http://www.jidc.org/index.php/journal/article/view/32012129 DB - PRIME DP - Unbound Medicine ER -